Filtered By:
Condition: Multidrug Resistance

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 957 results found since Jan 2013.

Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma
Multidrug resistance-associated protein 1 (MRP1) overexpression plays a major role in chemoresistance in glioblastoma multiforme (GBM) contributing to its notorious deadly nature. Although MRP1-siRNA transfect...
Source: Journal of Nanobiotechnology - April 13, 2018 Category: Nanotechnology Authors: Wing Yin Tong, Mohammed Alnakhli, Richa Bhardwaj, Sinoula Apostolou, Sougata Sinha, Cara Fraser, Tim Kuchel, Bryone Kuss and Nicolas H. Voelcker Tags: Research Source Type: research

Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy
Publication date: 30 July 2018 Source:International Journal of Pharmaceutics, Volume 546, Issues 1–2 Author(s): Jun Li, Huamin Liang, Jing Liu, Ziyuan Wang Poly (amidoamine) (PAMAM) dendrimers are well-defined, highly branched macromolecules with numerous active amine groups on the surface. Because of their unique properties, PAMAM dendrimers have steadily grown in popularity in drug delivery, gene therapy, medical imaging and diagnostic application. This review focuses on the recent developments on the application in PAMAM dendrimers as effective carriers for drug and gene (pDNA, siRNA) delivery in cancer therapy, incl...
Source: International Journal of Pharmaceutics - May 26, 2018 Category: Drugs & Pharmacology Source Type: research

DNA Origami Frameworks Enabled Self ‐Protective siRNA Delivery for Dual Enhancement of Chemo‐Photothermal Combination Therapy
Octahedral DNA origami frameworks (OctDOFs) are constructed for sterically enveloping and efficiently delivering siRNAs for chemo-photothermal combination cancer therapy. The confined space created by this nanoscaffold is able to shield the inward anchored siRNAs from degradative RNases during blood circulation, thus achieved dual sensitization of cancer cells to chemodrugs and hyperthermia. AbstractAlthough chemotherapy and photothermal therapy are widely used to combat cancer, their efficacy is often limited by multidrug resistance. Small interfering RNAs (siRNAs) have ability to suppress the expression of target genes, ...
Source: Small - October 6, 2021 Category: Nanotechnology Authors: Tingting Xu, Sha Yu, Yao Sun, Shaojun Wu, Di Gao, Mingyang Wang, Zhenzhen Wang, Ye Tian, Qianhao Min, Jun ‐Jie Zhu Tags: Research Article Source Type: research

Edible and cation-free kiwi fruit derived vesicles mediated EGFR-targeted siRNA delivery to inhibit multidrug resistant lung cancer
Clinically, activated EGFR mutation associated chemo-drugs resistance has severely threaten NSCLC patients. Nanoparticle based small interfering RNA (siRNA) therapy representing another promising alternative b...
Source: Journal of Nanobiotechnology - February 5, 2023 Category: Nanotechnology Authors: Haoying Huang, Xiaohan Yi, Qingyun Wei, Mengyuan Li, Xueting Cai, Yan Lv, Ling Weng, Yujie Mao, Weiwei Fan, Mengmeng Zhao, Zhongpei Weng, Qing Zhao, Kewei Zhao, Meng Cao, Jing Chen and Peng Cao Tags: Research Source Type: research

Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway
In conclusion, the present study elucidated that the activity of SMYD2 in NSCLC may affect the cell sensitivity to chemotherapeutic agents, especially to CDDP. The elevated SMYD2 mediated CDDP resistance and malignant phenotype in NSCLC, indicating that SMYD2 may be a useful biomarker of CDDP resistance in NSCLC. Inhibition of SMYD2 contributes to the methylation-related activation of p53 and thus results in cell apoptosis. Furthermore, combination treatment with CDDP and an SMYD2 inhibitor had a synergistically antitumor effects in a xenograft model in vivo. Given that SMYD2 has reversible effects and is a targetable prot...
Source: Frontiers in Oncology - April 25, 2019 Category: Cancer & Oncology Source Type: research

Resveratrol Promotes Diabetic Wound Healing via SIRT1-FOXO1-c-Myc Signaling Pathway-Mediated Angiogenesis
Conclusion: Our findings indicate that the positive role of RES in diabetic wound healing via its SIRT1-dependent endothelial protection and pro-angiogenic effects involves the inhibition of FOXO1 and the de-repression of c-Myc expression. Introduction Diabetes mellitus is a metabolic disease with an increasing incidence worldwide (Zimmet et al., 2014). The disease often leads to the development of serious complications such as microangiopathy, mainly including retinopathy, nephropathy, neuropathy, and diabetic non-healing skin ulcers (Zheng et al., 2018). Diabetic non-healing skin ulcers such as foot ulcers are ca...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH
In conclusion, LncRNA MVIH is upregulated in drug resistant NSCLC cells. Nedaplatin can reduce the expression of MVIH and reverse EMT process, thus reversing the drug resistance of cisplatin in non-small cell lung cancer cells.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Changwen Jing, Zhuo Wang, Rui Lou, Jianzhong Wu, Chen Shi, Dan Chen, Rong Ma, Siwen Liu, Haixia Cao, Jifeng Feng Tags: Research Paper Source Type: research

Co ‐delivery of hypoxia inducible factor‐1α small interfering RNA and 5‐fluorouracil to overcome drug resistance in gastric cancer SGC‐7901 cells
ConclusionsCo‐delivery of siRNA and 5‐fluorouracil chitosan nanoparticles is an attractive strategy for overcoming multidrug resistance.
Source: The Journal of Gene Medicine - December 11, 2017 Category: Genetics & Stem Cells Authors: Yunna Chen, Li Sun, Dongdong Guo, Ziteng Wu, Weidong Chen Tags: RESEARCH ARTICLE Source Type: research

Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines
CONCLUSION: Lipofectamine 2000 was the least toxic transfection reagent in osteo- and chondrosarcoma. Successful siRNA-induced MDR1 mRNA silencing of over 80% was achieved.PMID:37148005 | DOI:10.4103/jcrt.JCRT_565_19
Source: Cell Research - May 6, 2023 Category: Cytology Authors: Sarah S Freund Michael M Bendtsen Akmal Safwat Peter H Joergensen Source Type: research

FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein
Abstract F-box/WD repeat-containing protein 7 (FBW7) is a member of the F-box protein family that regulates cell cycle progression and cell growth and differentiation. FBW7 also functions as a tumor suppressor. A cisplatin (CDDP)-based multidrug chemotherapy regimen is standard for nasopharyngeal carcinoma (NPC), but drug resistance is an increasing problem. Here, we evaluated the relationship between FBW7 and multidrug resistance-associated protein (MRP), and its correlation with drug resistance in NPC, and explored the mechanism underlying drug resistance to CDDP in this disease. We used cell viability assays, W...
Source: Tumor Biology - January 14, 2015 Category: Cancer & Oncology Source Type: research

Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling
In this study, we aimed to investigate the potential anti-proliferative and pro-apoptotic activities of SNG in a panel of MM cell lines (U266, IM9, MM1S, and RPMI-8226). SNG treatment of MM cells resulted in a dose-dependent decrease in cell viability through mitochondrial membrane potential loss and activation of caspase 3, 9, and cleavage of PARP. Pre-treatment of MM cells with a universal caspase inhibitor, Z-VAD-FMK, prevented SNG mediated loss of cell viability, apoptosis, and caspase activation, confirming that SNG-mediated apoptosis is caspase-dependent. The SNG-mediated apoptosis appears to be resulted from suppres...
Source: Frontiers in Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Abstract 4590: Cisplatin-RNAi nanotherapeutics for synergistic anti-tumor activity
Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad spectrum of malignancies. However, the development of acquired chemoresistance is a persistent clinical problem limiting the successful treatment of malignancies and considerable work has been done to identify the molecular mechanisms involved. Many possible mechanisms have been suggested for platinum resistance emergence, such as drug efflux, apoptosis inhibition among others. Recent studies have shown that the suppression of crucial gene products (e.g. REV1, REV3L) involved in the error-prone translesion DNA synthesis pathway can sensitiz...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Xu, X., Zhang, X., Xie, K., Walker, G., Farokhzad, O. Tags: Experimental and Molecular Therapeutics Source Type: research

Multifunctional Micelles for the Reversal of Drug Resistance
Ovarian cancer is a dreadful disease estimated to be the second most common gynecologic malignancy worldwide. Its current therapy, based on cytoreductive surgery followed by the combination of platinum and taxanes, is frequently complicated by the onset of multidrug resistance (MDR). The discovery that survivin, a small antiapoptotic protein, is involved in chemoresistance provided a new prospect to overcome MDR in cancer, because siRNA could be used to inhibit the expression of survivin in cancer cells. With this in mind, we have developed self-assembly polymeric micelles (PM) able to efficiently co-load an anti–sur...
Source: Molecular Cancer Therapeutics - April 9, 2015 Category: Cancer & Oncology Authors: Salzano, G., Navarro, G., Trivedi, M. S., De Rosa, G., Torchilin, V. P. Tags: Models and Technologies Source Type: research

Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
The objective is to discuss the strategies for nanocarrier-based co-delivery systems using siRNA/anticancer drug combinations, emphasizing various siRNA targets that help overcome MDR and enhance therapeutic efficiency. PMID: 28523942 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - May 21, 2017 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research

Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy.
CONCLUSION: Inhibition of MRP1-4 by small interfering RNA enhanced and selectively restored sensitivity of hepatoma cells to drugs. MRP1-4 siRNA might represent a new therapeutic option for HCC. PMID: 27398162 [PubMed]
Source: American Journal of Translational Research - July 12, 2016 Category: Research Tags: Am J Transl Res Source Type: research